BridgeBio
BBIO
Performance
About BridgeBio
BridgeBio is a biopharmaceutical company focused on designing transformative medicines for patients with genetic diseases and cancers driven by clear genetic drivers. It develops and advances therapies across its pipeline, including products like Attruby (acoramidis) and Nulibry (fosdenopterin), aiming to bring clinically meaningful cures to patients. The company emphasizes a platform that accelerates discovery and development, combining science and finance to support patients and partners. Headquartered in Palo Alto, California, BridgeBio engages in research, collaborations, and patient-focused initiatives to address rare genetic diseases and oncology indications.
Recent News
Regulatory Actions for May 7, 2026
This Sam Altman-Backed $1.8 Billion Startup Bets AI Can Get Drugs Through Clinical Trials Faster
BioMarin Notches Win in Study that Could Expand Use of Top-Selling Medicine
STAT+: Hims’ Sales Miss as Telehealth Competition Grows
BridgeBio’s Attruby Challenges Pfizer’s Vyndamax Legacy in Pivotal ATTR Trial
Rare Disease Vouchers Caught in Political Abyss. It Didn’t Have To Be This Way
Yuviwel Gets FDA Greenlight as First Once‑Weekly Treatment for Dwarfism in Children
Alfasigma Gains Neuro Treatment; BridgeBio Offers $550M in Notes
FDA Accepts BridgeBio’s Application for Potential First Limb-Girdle Muscular Dystrophy Drug
BridgeBio Q1 2026 Earnings Show Atruvio Revenue Surge to $180.6M
Despite Wide Support for Rare Disease, Voucher Program Caught Up in Senate's ICE Fight
Recent Deals
No recent deals for this company.